Growth Metrics

Plus Therapeutics (PSTV) Non-Current Debt (2016 - 2022)

Plus Therapeutics has reported Non-Current Debt over the past 10 years, most recently at $3.8 million for Q4 2022.

  • Quarterly Non-Current Debt fell 24.36% to $3.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2022, down 24.36% year-over-year, with the annual reading at $3.8 million for FY2022, 24.36% down from the prior year.
  • Non-Current Debt was $3.8 million for Q4 2022 at Plus Therapeutics, down from $4.1 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $5.0 million in Q4 2021 and troughed at $3.8 million in Q4 2022.